ERBB2 and non-small cell lung carcinoma: Targeted therapies against oncogene-driven NSCLC, including EGFR[2], BRAF[10], and HER2 mutations[11] or ALK[3], ROS1[5], and RET[12] rearrangements, have been proved to improve outcomes, and they form the standard first-line treatment in patients with advanced disease.